Status:
TERMINATED
Prospective Cohort of Kidney Transplanted Patients Receiving an Extended Releasing Tacrolimus-Everolimus Association
Lead Sponsor:
Poitiers University Hospital
Collaborating Sponsors:
Chiesi Farmaceutici S.p.A.
Conditions:
Kidney Transplant
Immunosuppression
Eligibility:
All Genders
18+ years
Brief Summary
The tacrolimus-Everolimus association is used as an immunospressive treatment after a kidney transplant. It combined immunosupressive properties of both products and reduce the nephrotoxicity of tacro...
Eligibility Criteria
Inclusion
- Patients over 18 years old
- Patients informed and giving his agreement to the use of every collected data
- Patients with kidney transplantation for at least one year and being treated with the immunosppressive assiociation of Tacrolimus (Prograf ®)-Everolimus
- Patients whose investigators decides to switch from Prograf ® to an Envarsus ®-Everolimus association
Exclusion
- Other transplantation
- Drug or alcohol abuse
- Patients unable to understand the purpose or modalities of this study, unable to give his agreement or unable to stick to the protocol
- Patients on an interventionnal protocol when included
Key Trial Info
Start Date :
April 14 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 18 2018
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT03228576
Start Date
April 14 2017
End Date
December 18 2018
Last Update
August 28 2019
Active Locations (9)
Enter a location and click search to find clinical trials sorted by distance.
1
Amiens University Hospital
Amiens, France, 80000
2
Angers University Hospital
Angers, France, 49100
3
Caen University Hospital
Caen, France, 14033
4
Clermont Ferrand University Hospital
Clermont-Ferrand, France, 63000